TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04562116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYP 450 Substrates
Description: CYP substrates (Caffeine, Warfarin Sodium, Midazolam, Omeprazole, and Metoprolol Tartrate) will administered orally at Week 0 (Day 1) and Week 10 as per the commercially available prescribing information.
Study: NCT04376528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Description: Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with cyclosporin A)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with mycophenolate mofetil )
Study: NCT05000216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withhold IS (MMF or MPA)
Description: Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withhold IS (MMF or MPA)
Description: Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.
Study: NCT06310928

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermal Blanket
Description: Thermal blankets, a passive heating blanket, have a silver surface to prevent heat loss through radiation. Thermal insulation is achieved thanks to the fact that they are covered with a reflective surface to reflect light radiation, i.e. thermal radiation. It is a cost-effective, easy-to-clean, flexible material that takes the desired shape. Thermal blankets generate heat by providing thermal insulation with infrared radiation and can provide thermal vasodilation or thermotherapy. In 2013, Lima et al. used infrared thermal blankets to provide thermal vasodilation and as a result, it was found to reduce vascular resistance. Therefore, FORCLAZ brand blanket, also known as emergency blanket, used in natural disaster management, peripheral vascular resistance studies and hypothermia prevention studies was used in this study.
Study: NCT05609916

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: During Phase I, participants will receive open label (no blinding) CBT during their study participation for 12 to 18 weeks.~During Phase II, participants will continue receiving CBT maintenance sessions every two weeks for the first 4 weeks, followed by sessions every four weeks. They will also meet with the study physician every 2 weeks via telepsychiatry appointments for clinical and scalar assessment.
Study: NCT06284031

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3 fractions HDR brachytherapy
Description: The 3 fractions of HDR brachytherapy may be delivered in the following ways:~Option 1: 3 insertions over 2 non-consecutive days:~Option 2: 3 insertions over 3 non-consecutive days
Study: NCT05831943

Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast enhanced Kidney CT
Description: * Test group : Patient undergoing CT scan with 80kVP protocol and using low concentration intravascular contrast media ( Iobrix 270 mgl/MI , Taejoon pharm, Seoul, South Korea)~* Control group : Patient undergoing CT scan with 120kVP protocol and using high concentration intravascular contrast media ( Iobrix 320 mgl/MI , Taejoon pharm, Seoul, South Korea)
Study: NCT05609916

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: During Phase I, participants will receive open label (no blinding) CBT during their study participation for 12 to 18 weeks.~During Phase II, participants will continue receiving CBT maintenance sessions every two weeks for the first 4 weeks, followed by sessions every four weeks. They will also meet with the study physician every 2 weeks via telepsychiatry appointments for clinical and scalar assessment.
Study: NCT05000216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withhold IS (B cell depletion therapy)
Description: Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX ) before and after the additional vaccine dose per protocol instructions. Participants will continue to take their prescribed BCDTs without alterations in schedule and dosing.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273, Bivalent
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273, Bivalent
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273, Bivalent
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273, Bivalent
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273, Bivalent
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273, Bivalent
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273, Bivalent
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273, Bivalent
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273, Bivalent
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273, Bivalent
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273, Bivalent
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273, Bivalent
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273, Bivalent
Description: Administration: One dose administered intramuscularly.
Study: NCT05136378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Selenious Yeast Tablets
Description: Low dose of Selenious Yeast Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Selenious Yeast Tablets
Description: High Dose Selenious Yeast Tablets
Study: NCT05000216

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273, Bivalent
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2, Bivalent
Description: Administration: One dose administered intramuscularly.
Study: NCT05960461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FMF (Families Moving Forward) Connect Pro
Description: FMF Connect Pro is a program supported by mental health providers to increase access to care for children (ages 3 to 12) with fetal alcohol spectrum disorders (FASD) and their families. FMF Connect Pro teaches and supports providers in 3 main activities:~1. Routine screening of prenatal alcohol exposure (PAE)~2. Apply DSM-5 diagnostic criteria for Neurodevelopmental Disorder Associated with Prenatal Alcohol Exposure (ND-PAE)~3. Support caregivers using the FMF Connect app~FMF Connect Pro involves a Provider Dashboard with several main sections:~* Learning - includes content and additional resources to support providers in learning how to screen PAE, diagnose ND-PAE, and support families using the FMF Connect app.~* Tools and Resources - includes: screening, diagnostic, and documentation templates; app tip sheets; workbooks; supporting articles, websites, and other resources~* Clients - providers can track clients' progress using the FMF Connect app

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FMF (Families Moving Forward) Connect Pro
Description: FMF Connect Pro is a program supported by mental health providers to increase access to care for children (ages 3 to 12) with fetal alcohol spectrum disorders (FASD) and their families. FMF Connect Pro teaches and supports providers in 3 main activities:~1. Routine screening of prenatal alcohol exposure (PAE)~2. Apply DSM-5 diagnostic criteria for Neurodevelopmental Disorder Associated with Prenatal Alcohol Exposure (ND-PAE)~3. Support caregivers using the FMF Connect app~FMF Connect Pro involves a Provider Dashboard with several main sections:~* Learning - includes content and additional resources to support providers in learning how to screen PAE, diagnose ND-PAE, and support families using the FMF Connect app.~* Tools and Resources - includes: screening, diagnostic, and documentation templates; app tip sheets; workbooks; supporting articles, websites, and other resources~* Clients - providers can track clients' progress using the FMF Connect app

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECHO (Extension of Community Healthcare Outcomes) implementation.
Description: Mental health providers participate in a 13-session tele-mentoring training program using the ECHO (Extension of Community Healthcare Outcomes) approach. Each session involves a brief didactic presentation and case-based learning using de-identified cases shared by participants. The curriculum teaches providers how to do FMF Connect Pro.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Directed Learning implementation.
Description: Mental health providers complete 13 learning modules asynchronously on the FMF Connect Pro Dashboard. These modules include pre-recorded didactic content, brief exercises to assess learning, and additional resources. The curriculum teaches providers how to do FMF Connect Pro.
Study: NCT04010890

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally adapted CBT
Description: Culturally adapted CBT for South Asian Canadians

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Culturally adapted CBT
Description: Culturally adapted CBT for South Asian Canadians
Study: NCT05700955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab and Temozolomide
Description: Characterize the safety and immunologic/genomic/metabolomic effects of neoadjuvant Pembrolizumab and Temozolomide in recurrent glioblastoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab and Temozolomide
Description: Characterize the safety and immunologic/genomic/metabolomic effects of neoadjuvant Pembrolizumab and Temozolomide in recurrent glioblastoma.
Study: NCT05000216

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2, Bivalent
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2, Bivalent
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2, Bivalent
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2, Bivalent
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2, Bivalent
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2, Bivalent
Description: Administration: One dose administered intramuscularly.
Study: NCT05435144

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elderberry
Description: European black elderberry extract

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive placebo
Study: NCT05609916

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy
Description: During Phase I, participants will receive open label (no blinding) CBT during their study participation for 12 to 18 weeks.~During Phase II, participants will continue receiving CBT maintenance sessions every two weeks for the first 4 weeks, followed by sessions every four weeks. They will also meet with the study physician every 2 weeks via telepsychiatry appointments for clinical and scalar assessment.
Study: NCT05990582

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CBCL
Description: A questionnaire on behaviour

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CBCL
Description: A questionnaire on behaviour

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: SDQ
Description: A questionnaire on behaviour

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SDQ
Description: A questionnaire on behaviour

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CCC-2-NL
Description: A questionnaire on communcational skills

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CCC-2-NL
Description: A questionnaire on communcational skills

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MCH Feeding scale
Description: A questionnaire on feeding problems

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MCH Feeding scale
Description: A questionnaire on feeding problems

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: TRF
Description: A questionnaire on behaviour

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TRF
Description: A questionnaire on behaviour

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: WISC-5-NL
Description: An IQ test for children

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: WISC-5-NL
Description: An IQ test for children

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Movement ABC
Description: A test to assess motor function

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Movement ABC
Description: A test to assess motor function

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CELF-5-NL
Description: A test to assess language development

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CELF-5-NL
Description: A test to assess language development

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Emma Toolbox
Description: Test of executive functions

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Emma Toolbox
Description: Test of executive functions
Study: NCT06406439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Insulin Pen
Description: The subject allocated to the intervention or control group through randomization will visit hospital maximun 5 times during the 12-week application period, including the baseline visit, in the following process.
Study: NCT05089344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Description: growth hormone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate daily and recombinant FSH (Gonal-F®)
Description: Clomiphene citrate daily and recombinant FSH (Gonal-F®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate daily and recombinant FSH (Gonal-F®)
Description: Clomiphene citrate daily and recombinant FSH (Gonal-F®)
Study: NCT05000216

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2, Bivalent
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2, Bivalent
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2, Bivalent
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2, Bivalent
Description: Administration: One dose administered intramuscularly.
Study: NCT05933551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Z Technique Training
Description: Training on Z technique will be given on the planned day, time and place. The education is planned to be given at Tarsus University. The training content will be presented to the participants as a powerpoint presentation (30 min), laboratory practice (15 min) and question-answer (15 min).
Study: NCT06250413

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: FMT
Description: Capsulated oral auto fecal microbiota transplant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMT
Description: Capsulated oral auto fecal microbiota transplant

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsulated hot chocolate powder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsulated hot chocolate powder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amox Clav
Description: 5 day course of Amoxicillin Clavulanic acid given to all participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amox Clav
Description: 5 day course of Amoxicillin Clavulanic acid given to all participants
Study: NCT05559112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D-enriched mushrooms
Description: Participants will consume their usual, unrestricted, self-selected diet plus 84 g of vitamin D-enriched mushrooms twice daily (for a total of 168g per day) for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Study Powder
Description: Participants will consume their usual, unrestricted, self-selected diet plus 1 tsp of dried study powder twice daily (2 tsp total per day) for 12 weeks. Study powder is a commercially available carbohydrate.
Study: NCT05177562

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention in this study

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention in this study

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention in this study

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention in this study

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention in this study

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention in this study
Study: NCT04769765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Definition of the Individualized Care Pathway
Description: Implementation of an individualized care pathway defined in concertation with a multidisciplinary tele-expertise meeting held every 3 months for one year. These multidisciplinary tele-expertise meetings will be held between each of the normal routine consultations which are part of the normal, basic diabetic program which includes a consultation with a dietitian, monitoring by a state-registered nurse and treatment prescribed by the patient's general practitioner (with or without a consultation with the clinical pharmacist).
Study: NCT05177562

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention in this study

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention in this study

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention in this study

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention in this study
Study: NCT04764656

Intervention type: DRUG
Intervention: Brolucizumab
Description: There is no treatment allocation. Patients administered Brolucizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
Study: NCT06041841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB54640
Description: LB54640 QD Oral
Study: NCT06555718

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The Peer Support Program
Description: Implementation of the research; Peer support programme for the intervention group will be carried out for 10 weeks in accordance with the peer guide-client implementation plan. Standard follow-up and training programme will be applied to the control group in accordance with the procedures of the institution.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standart care
Description: The standard care provided by the institution will continue.
Study: NCT05889234

Intervention type: DEVICE
Intervention: Modified Electroconvulsive Therapy
Description: MECT is performed using the Thymatron System IV (Somatics LLC, LakeBluff, IL, USA) electroconvulsive therapy (ECT) machine. Prior to ECT, all patients undergo laboratory tests such as routine blood, liver, kidney and thyroid function and an ECG and remain fasted for 12 hours. Initial treatment power is considered by age: percentage of power = age x 0.7. Stimulation power is adjusted according to seizure duration. If the seizure duration is less than 25 seconds, the energy is increased by 5% in the subsequent treatments. Anaesthesia and muscle relaxation were administered with propofol (1.5-2 mg/kg) and succinylcholine (0.5-1 mg/kg), respectively, and subjects were awakened after ECT treatment and adverse effects, such as subjective memory impairment, headache or nausea/vomiting, were recorded. Frequency of ECT treatment: 3-4 times per week for a total of 6-8 sessions

Intervention type: DRUG
Intervention: Conventional pharmacotherapy
Description: Conventional pharmacotherapy: SSRIs including fluoxetine, paroxetine, sertraline, cetinopram, fluvoxamine, vortioxetine, escitalopram; SNRIs including venlafaxine, duloxetine; NaSSA including mirtazapine; other antidepressants including trazodone, bupropion, agomelatine; potentiators including aripiprazole, olanzapine, quetiapine, risperidone.

Intervention type: DRUG
Intervention: Conventional pharmacotherapy
Description: Conventional pharmacotherapy: SSRIs including fluoxetine, paroxetine, sertraline, cetinopram, fluvoxamine, vortioxetine, escitalopram; SNRIs including venlafaxine, duloxetine; NaSSA including mirtazapine; other antidepressants including trazodone, bupropion, agomelatine; potentiators including aripiprazole, olanzapine, quetiapine, risperidone.
Study: NCT05799027

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Raman spectrum
Description: The bronchoscopic biopsy sample of patients with visible lesions in the airway would undergo raman spectrum analysis.
Study: NCT06216158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iberdomide
Description: Iberdomide p.o. (1.0 mg, day 1-21 of each 29-days cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Iberdomide p.o. (1.0 mg, day 1-21 of each 29-days cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab s.c. (1400 mg, cycle 1: day 1, 8, 15, 22; cycles 2-3: day 1 and 15; from C4: day 1)